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Research addressing the occurrence, fate and effects of pharmaceuticals in the aquatic environment has
expanded rapidly over the past two decades, primarily due to the development of improved chemical
analysis methods. Signiﬁcant research gaps still remain, however, including a lack of longer term,
repeated monitoring of rivers, determination of temporal and spatial changes in pharmaceutical con-
centrations, and inputs from sources other than wastewater treatment plants (WWTPs), such as com-
bined sewer overﬂows (CSOs). In addressing these gaps it was found that the ﬁve pharmaceuticals
studied were routinely (51e94% of the time) present in efﬂuents and receiving waters at concentrations
ranging from single ng to mg L1. Mean concentrations were in the tens to hundreds ng L1 range and
CSOs appear to be a signiﬁcant source of pharmaceuticals to water courses in addition to WWTPs.
Receiving water concentrations varied throughout the day although there were no pronounced peaks at
particular times. Similarly, concentrations varied throughout the year although no consistent patterns
were observed. No dissipation of the study compounds was found over a 5 km length of river despite no
other known inputs to the river. In conclusion, pharmaceuticals are routinely present in semi-rural and
urban rivers and require management alongside more traditional pollutants.
© 2016 Elsevier Ltd. All rights reserved.1. Introduction
An increasing global population is placing great strain on over
65% of the Earth's rivers with chemical pollution one of the main
causes of degradation and biodiversity loss in aquatic ecosystems
(Vorosmarty et al., 2010). In chemical pollution research there has
been an increasing focus on emerging contaminants over recent
decades (Daughton and Ternes, 1999) which enter the aquatic
environment following excretion or disposal to the sewer system
and passage through wastewater treatment plants (WWTPs)
(Kolpin et al., 2002). It is now widely considered that WWTP
efﬂuent is the dominant route by which pharmaceuticals enter the
aquatic environment (Heberer, 2002; Daughton, 2004; Jones et al.,
2005; Tambosi et al., 2010). Although the likelihood of human
health impacts due to pharmaceuticals in the environment is lowe by Dr. Chen Da.
ool House, St Joseph's Street,their presence in continually discharged efﬂuent is a major
ecological concern due to the potential for effects on aquatic or-
ganisms at trace concentrations (Daughton, 2001; Cleuvers, 2003,
2004; Fent et al., 2006; Caliman and Gavrilescu, 2009;
Kümmerer, 2009; Santos et al., 2010).
Research into pharmaceutical pollution is expanding largely due
to increased concern over potential adverse effects and advance-
ments in the analytical techniques necessary to detect such com-
pounds at trace concentrations (Daughton, 2001; Williams, 2005).
Although chemical analysis methods have been improved greatly,
there remains a dearth of research which uses these to quantify the
occurrence of pharmaceuticals throughout river catchments over
periods of time, as has been done for other chemicals such as
metals, nutrients (Neal et al., 2012) and pesticides (Bundschuh
et al., 2014). Very little work has been conducted in large parts of
Africa, Asia, the Middle East and South America and even within
those countries with a relatively high level of research the number
of studies undertaken remains very small compared to other
groups of chemicals (Hughes et al., 2013). Of 155 published phar-
maceutical monitoring studies 80% were reported to have been
carried out in the US and Europe (Hughes et al., 2013). Furthermore,
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number of studies exist, spatial bias exists in pharmaceutical
occurrence datasets. For example, UK pharmaceutical pollution
monitoring is heavily clustered around south east England and
parts of south Wales with very few studies in central, western and
northern England or Scotland where large urban areas exist. Where
studies are present they often rely on non-repeated sampling and
have typically provided very few details on the adopted sampling
regime, making it difﬁcult to draw conclusions about the reliability
or representativeness of the data presented (Hughes et al., 2013).
In addition to WWTPs, combined sewer overﬂows (CSOs) and
misconnections to storm water drains, which could lead to the
discharge of untreated sewage efﬂuent to receiving waters, have
been identiﬁed as potential sources of pharmaceutical pollution.
Despite this, there are very few studies which attempt to examine
the contribution they make to overall pharmaceutical loads in
rivers (Boyd et al., 2004; Kolpin et al., 2004). This is of concern as it
has been hypothesised that such non-WWTP point sources may
actually be the key contributor of high pharmaceutical concentra-
tions in reaches far from WWTP efﬂuent outfalls and where dissi-
pation has not been found to occur downstream of WWTPs (Ellis,
2006). Residual low levels of pharmaceuticals have been detected
tens or hundreds of kilometres downstream of WWTP outfalls
(Waiser et al., 2011), demonstrating the potential for widespread,
catchment-level impacts. This presents a pressing research need
given the assumption in many risk assessment models of ﬁrst-
order, in-stream decay of pharmaceuticals (Schowanek et al.,
2001). Only 16% of monitoring studies included in a recent critical
review paper collected samples more than 1 km downstream of
WWTP outfalls, indicating a tendency for research to focus on the
efﬂuent dominated reaches immediately downstream (Hughes
et al., 2013). This is understandable given the likelihood that
these areas are most affected by pharmaceutical pollution but this
often leaves long reaches of catchments with little or no pharma-
ceutical monitoring data available.
Research examining temporal variation in pharmaceutical con-
centrations in receiving waters is also rare, despite some evidence
demonstrating high degrees of variation over hourly and daily
periods (Kanda et al., 2003) as well as seasons (Lindholm-Lehto
et al., 2016; Papageorgiou et al., 2016). Given the tendency to-
wards non-repeated grab sampling of receiving waters it is unlikely
that such variation has so far been adequately captured in existing
monitoring datasets and they may therefore currently give an
inaccurate description of the occurrence of pharmaceuticals in
rivers (Ort and Gujer, 2006; Ort et al., 2010a, b).
Given the highlighted research gaps, the aims of the current
study were to: carry out repeated sampling of river reaches
throughout an eighteen month period for ﬁve pharmaceuticals;
monitor the chemicals’ presence inWWTP and CSO efﬂuent as well
as their receiving waters; undertake diurnal monitoring of phar-
maceuticals in the receiving waters of WWTPs; and examine
dissipation of the study compounds over a 5 km river reach.
2. Methods
2.1. Study area and sampling sites
The Aire and Calder catchments, West Yorkshire, UK, are ideal
for studying the occurrence of pharmaceuticals in rivers given the
105 WWTPs that discharge efﬂuent into them (Fig. 1). The catch-
ments are heavily urbanised in the lower reaches with the West
Yorkshire Urban Area being one of the ten most populous areas of
the UK and being home to around 1.5 million people (Pointer,
2005). There are also a number of smaller towns and villages in
the semi-rural and rural upland parts of the catchments. In additionto the WWTPs there are estimated to be 70 CSOs spread across the
entire catchment area (Environment Agency, 2010). The total
catchment areas of the Aire and Calder above the tidal limit are
1932 and 899 km2 respectively. Mean annual discharges in the
downstream reaches of the catchments are 36 and 19 m3 s1
(Carter et al., 2006). Seven WWTPs (supplementary material S1 for
treatment techniques and populations served) were monitored
monthly for eighteen months and ﬁve CSOs were sampled during
periods of intensive rainfall which caused them to discharge. More
spatially intensive reach monitoring, below one of the WWTPs
(Knostrop), was undertaken on seven occasions to look at phar-
maceutical dissipation downstream of speciﬁc WWTP discharges.
This was done over a 5 km length of river; the distance to the next
WWTW downstreamwhere more efﬂuent would have entered the
river. Diurnal sampling was undertaken on two occasions at Gar-
forth and OultonWWTPs with samples being collected every 3 h at
each.
2.2. Sample collection procedure
Grab samples of efﬂuent (WWTP and CSO) and receiving
channel water (0.8 L) for all ﬁeld surveys were collected in 1 L
amber silanised glass bottles with Teﬂon® lined caps (Fisher Sci-
entiﬁc, Leicestershire, UK) and kept chilled in the dark during
transit. Samples of WWTP efﬂuent and receiving waters were
collected at the start of each month at the same time of day to
minimise errors associated with diurnal ﬂuctuations in pharma-
ceutical concentrations (Kanda et al., 2003). Receiving water sam-
ples were collected at a point of ﬁve times the stream width
downstream of the efﬂuent outfall to allow for mixing (Morris,
2013). Samples were collected from the centre of the stream at
50% depth in-line with established guidelines (USGS, 2006) where
possible, or otherwise, due to the size of the channel and bank
topography, at the bankside (downstream of Heaton Lodge, Hor-
bury Junction, Oulton/Lemonroyd, and Knostrop WWTP). CSO
samples were collected during storm events when the CSOs were
discharging to streams and the release of untreated efﬂuent could
have an impact on them. All apparatus and glassware used during
sample collection and preparation was thoroughly washed with
100% methanol (1 x) and de-ionised water (3 x) prior to each use to
remove potential contamination. On return to the laboratory,
samples were stored in the dark at 4 C and extracted within 48 h.
2.3. Study compounds
Five study compounds (Table 1) were chosen based on risk
quotients (RQ) (ratio of predicted or maximum environmental
concentration to predicted no effect concentration) produced in
previously published studies (Jones et al., 2002; Thompson, 2006;
Yamamoto et al., 2009). A RQ  1 indicates the potential for im-
pacts on aquatic organisms so this was used as the basis for se-
lection and the number of compounds limited to ﬁve to focus on
high risk substances.
2.4. Analysis of receiving water and efﬂuent samples
Pharmaceutical standards were used to create working and
stock solutions in dilution series for calibration of analytical in-
struments. All pharmaceuticals were supplied by Sigma-Aldrich
Company Ltd. (Dorset, UK) and were of the highest purity avail-
able (>99%). Individual stock standard solutions (1000 ng L1) were
prepared on aweight basis in 100%methanol and stored in the dark
at 20 C until used. A fresh working mixture solution of all
pharmaceuticals was prepared by appropriate dilution of the in-
dividual stocks in methanol-water (20:80, v/v) immediately before
Fig. 1. Map of wastewater treatment plants (WWTPs), combined sewer overﬂows (CSOs) and river reach sampling sites. (Based on unpublished data supplied by the Environment
Agency and Yorkshire Water).
Table 1
Structure and properties of the ﬁve study compounds. Risk quotients from Jones et al. (2002), Thompson (2006) and Yamamoto et al. (2009). Physicochemical data from Ternes
(1998), Kasprzyk-Hordern et al. (2007), NIH (undated), Knox et al. (2010) and USEPA (2014).
Compound Therapeutic use Structure Physico-chemical properties and risk quotients
Diclofenac Non-steroidal anti-inﬂammatory drug (NSAID) MW ¼ 296.15
Solubility (mg L1) ¼ 2430
pKa ¼ 4.0
log KOW ¼ 4.02
RQmin ¼ 0.01
RQmax ¼ 1.13
Erythromycin Macrolide antibiotic MW ¼ 733.95
Solubility (mg L1) ¼ 1.44
pKa ¼ 8.9
log KOW ¼ 2.48
RQmin ¼ 0.01
RQmax ¼ 1.25
Ibuprofen NSAID MW ¼ 206.29
Solubility (mg L1) ¼ 21
pKa ¼ 4.91
log KOW ¼ 3.79
RQmin ¼ 0.55
RQmax ¼ 4.20
Mefenamic acid NSAID MW ¼ 241.29
Solubility (mg L1) ¼ 20
pKa ¼ 4.2
log KOW ¼ 5.12
RQmin ¼ 1.03
RQmax ¼ 8.31
Propranolol Non-selective beta-blocker MW ¼ 259.35
Solubility (mg L1) ¼ 31
pKa ¼ 9.4
log KOW ¼ 2.60
RQmin ¼ 0.49
RQmax ¼ 4.25
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Working standards were also stored in the dark at 20 C between
uses. HPLC-grade methanol was supplied by Fisher Scientiﬁc UK
Limited (Loughborough, UK) and deionised water by a Purite Select
HP160/BP/IT deioniser. The SPE procedure and subsequent analysis
by HPLC and Q-TOF MS/MS followed an established method
(Petrovic et al., 2006). 800 mL of unﬁltered sample was measured
for SPE using a 20-position Waters vacuum extraction manifold in
conjunction with Oasis HLB SPE cartridges (6 cc, 150 mg; Waters
Corporation, Milford, MA, USA). First the SPE cartridges were
conditioned with 5 mL 100%methanol followed by 5mL de-ionised
water at a ﬂow rate of 1 mL min1. The 800 mL river and efﬂuent
samples were then loaded onto the SPE cartridge at a ﬂow rate of
10 mL min1 during which care was taken not to let the sorbent
material dry out. The cartridges were then rinsed with 5 mL de-
ionised water at a ﬂow rate of 1 mL min1 prior to being thor-
oughly air dried under vacuum for 15 min to remove excess water.
Elution of the cartridges was performed with 2  4 mL of 100%
methanol at a ﬂow rate of 1 mL min1 directly into glass centrifuge
tubes. The eluent was evaporated to dryness under vacuum
centrifugation and reconstituted in 0.5 mL of methanol: water
(20:80, v/v). Sample extracts were stored in the dark at20 C prior
to analysis which was performed using an Ultimate 3000 nanoLC
system (Dionex) and 2.1  100 mm Acclaim RSLC 120 C18 2.2 mm
particle silica column. In positive ion (PI) mode a solvent system of
5 mM ammonium acetate/acetic acid (pH 2.4; buffer A) and
methanol-acetonitrile (2:1, v/v, buffer B) was used at a ﬂow rate of
0.3 mL min1 and the column held at a constant temperature
(30 C). In negative ion (NI) mode a solvent system of 2 mM
ammonium acetate (buffer A) and 2 mM ammonium acetate in
methanol-water (95:5, v/v, buffer B) was used at a ﬂow rate of
0.3 mL min1 and the column held at 30 C. After injection, the
gradient was held at 5% B for 5 min followed by 5e80% B over
20 min. A 15 min column wash at 95% B and an equilibration of
5 min at 5% B was performed between each sample injection. The
LC eluent was directly infused into the Z-spray electrospray source
of a quadrupole-ion mobility-orthogonal time of ﬂight (Q-TOF)
mass spectrometer (Synapt HDMS, Waters UK). Electrospray des-
olvation temperaturewas 150 C and desolvation gas was 500 L h1,
capillary and cone voltages were 3.2 kV and 30 V respectively.
Backing pressure was 2.1 bar, the argon pressure in the trap and
transfer region of the IMS cell was 2.17 mbar. MS/MS analysis was
performed only on the target pharmaceutical compounds when
their intensity was greater than 10 counts per second and their
retention time was within ±1 min of that of the corresponding
standards. Trap collision energy used for each compound was
optimised individually between 15 and 30 V. The lockspray fre-
quency was set to one 1 s scan every 10 s. For PI mode a 5 mM so-
lution of Glu ﬁbrinopeptide in methanol/0.1% formic acid (50:50, v/
v) was used as the lock mass, in NI mode the m/z 276 peak of a
2 ng mL1 of sodium iodide in methanol water (50:50, v/v) was used
as the lock mass.
All data analysis was performed in MassLynx™ (v4.1, Waters
Ltd.). Positive identiﬁcation of the target pharmaceuticals was
based on accurate mass measurement of the parent ion within an
error of ±20 ppm, accurate mass of at least one product ion, also
within an error of ±20 ppm, and LC retention time of the target
analytewith reference to that of a standard (±5%). Quantitationwas
performed by constructing extracted ion chromatograms (XICs) of
the protonated (PI mode) and deprotonated (NI mode) ion using a
20 mDa window centred on the theoretical m/z of the compound
and taking the area of the resulting peak using MassLynx's inbuilt
integration algorithms.
Reproducibility of the method was tested with repeated in-
jections of a standard solution both sequentially and day-to-day.Instrumental detection limits (IDLs) were estimated using a stan-
dard solution in dilution series until reaching a concentration
yielding a signal: noise (S: N) ratio of three. Linear dynamic ranges
were determined for each compound by injecting a dilution series
of the working standard mixture solutions across a wide concen-
tration range (2e1000 ng L1). Calibration curves of peak area
(from XICs) vs. Concentration were created using linear regression
analysis and the linear range that gave good ﬁt (r2 > 0.95) was
established for each compound.
SPE recovery and signal suppression due to matrix effects were
evaluated by spiking known concentrations (20, 100 and
200 ng L1) of all of the study compounds into 3 replicates each of
deionised water and river water. As matrix effects using this
method have already been characterised well for the study com-
pounds (Petrovic et al., 2006), and our results were in good
agreement with these for deionised and river water, further matrix
effects tests in WWTP and CSO efﬂuent were not repeated. Based
on this previous work it was assumed that signal suppression in
WWTP efﬂuent would be between 0 and 10% for all of the com-
pounds other than erythromycin (25%). In CSO efﬂuent (based on
WWTW inﬂuent data in Petrovic et al. (2006)) this would be be-
tween 10 and 20% and 40% for erythromycin. The data presented
here for WWTP and CSO efﬂuent are, thus, likely to be slight un-
derestimates of actual concentrations. Method performance data
are provided in the supplementary material (S2).
3. Results
A total of 320 samples were collected, comprising 121 WWTP
efﬂuent, 185 receiving water and 14 CSO samples. The HPLC-MS/MS
method resulted in a quantitation limit of 5 ng L1 for all study
compounds except ibuprofen (25 ng L1).
3.1. Monthly sampling
A total of 121 WWTP efﬂuent (Table 2) and 125 receiving water
(Table 3) samples were collected during the monthly sampling
campaign. For diclofenac, erythromycin and ibuprofen, concentra-
tionswere usually in the order of hundreds of ng L1 although some
an order of magnitude higher (mg L1) were measured and
ibuprofen was often present at the highest concentration of the
three compounds. In contrast, mefenamic acid and propranolol
were detected at single and tens of ng L1. Detection frequencies
ranged between 51 and 94%. Although only 14 CSO samples were
collected, all ﬁve pharmaceutical compounds were present and
detection frequencies and concentrations were in the same range
as for WWTP efﬂuent and receiving waters (Table 4). The only
exception was ibuprofen for which mean and maximum CSO con-
centrations were an order of magnitude higher than in WWTP
efﬂuent and receiving waters. Flow conditions had little impact on
detection frequencies although signiﬁcant differences did exist in
concentrations across ﬂow categories with receiving water con-
centrations measured in high ﬂows being lower (supplementary
material S3). Nevertheless, concentrations were higher in me-
dium ﬂows than low ﬂows and so it may be that relatively high
concentrations are transient and higher mean concentrations were
detected in ﬂow conditions that were sampled more frequently,
medium ﬂows being most prevalent and high ﬂows the least.
3.2. Diurnal sampling
Concentrations of all ﬁve pharmaceutical compounds sampled
in the receiving waters of Garforth and Oulton WWTPs during
diurnal sampling varied by up to a factor of four within the same
day although changes were usually much smaller than this and no
Table 2
Pharmaceutical concentrations (ng L1) measured in the efﬂuent of seven wastewater treatment plants (WWTPs) in the River Aire and Calder catchments, UK, during an
eighteen month monitoring campaign. Max ¼ maximum, SD ¼ standard deviation, nd ¼ not detected, na ¼ not applicable.
WWTP n Diclofenac Erythromycin Ibuprofen Mefenamic acid Propranolol
Max Mean SD Max Mean SD Max Mean SD Max Mean SD Max Mean SD
Garforth 17 2830 590 887 1757 394 476 3593 780 829 30 11 8 1464 37 39
Heaton Lodge 17 1302 157 318 586 249 279 949 320 285 91 32 326 20 11 66
Horbury Junction 17 601 173 197 793 200 251 3645 1147 864 15 5 5 35 13 10
Knostrop 17 806 273 266 466 185 302 863 302 223 35 8 9 41 16 13
Oulton 18 994 231 238 1106 249 288 4617 794 1035 33 7 8 36 14 12
Oxenhope 17 401 61 94 1857 399 480 1068 363 319 nd nd na 35 15 11
Ripponden 18 411 111 148 782 240 258 2364 524 586 108 1078 na 1 10 5
All sites 2830 228 415 1857 274 348 4617 604 719 108 28 208 146 16 18
Detection frequency (%) 91 78 51 91 94
Five efﬂuent samples could not be collected due to some of the sites being inaccessible due to ﬂooding on one sampling occasion, therefore 121 samples were collected rather
than 126.
Table 3
Pharmaceutical concentrations (ng L1) measured in the receiving waters of sevenwastewater treatment plants (WWTPs) in the River Aire and Calder catchments, UK, during
an eighteen month monitoring campaign. Max ¼ maximum, SD ¼ standard deviation, na ¼ not applicable.
WWTP n Diclofenac Erythromycin Ibuprofen Mefenamic acid Propranolol
Max Mean SD Max Mean SD Max Mean SD Max Mean SD Max Mean SD
Garforth 18 2991 649 958 1378 403 307 2960 812 849 41 11 11 44 19 12
Heaton Lodge 18 284 88 87 413 143 127 1409 319 367 53 22 20 22
21.8
5 6
Horbury Junction 18 456 103 122 318 121 108 2172 415 569 97 24 29 7 4 2
Knostrop 18 937 323 307 845 230 254 4838 720 1091 39 12 11 165 30 38
Oulton 18 592 187 170 451 138 132 2770 457 639 23 11 8 25 8 17
Oxenhope 18 124 39 38 132 49 40 205 100 57 9 9 na 6 3 1
Ripponden 17 76 25 18 174 34 43 358 124 97 15 6 6 6 3 1
All sites 2991 202 438 1378 160 217 4838 421 680 97 11 16 165 10 20
Detection frequency (%) 93 94 93 66 70
One receiving water sample could not be collected due to the site being inaccessible at the time, therefore 125 samples were collected rather than 126.
Table 4
Pharmaceutical concentrations (ng L1) measured in combined sewer overﬂow (CSO) efﬂuent in the River Aire and Calder catchments, UK. nd ¼ not detected.
CSO n Diclofenac Erythromycin Ibuprofen Mefenamic acid Propranolol
Max Mean Max Mean Max Mean Max Mean Max Mean
Newlay Lane 1 161 161 1603 1603 76 76 nd nd nd nd
Canal Road 2 274 187 nd nd 278 143 35 19 nd nd
Commercial Road 4 175 74 727 256 10,060 2734 19 5 18 10
Oulton Beck 7 1805 388 243 98 14,231 2207 nd nd 29 11
All sites 1805 203 1603 489 14,231 1290 35 6 29 5
Detection frequency (%) 86 64 100 21 36
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Concentrations of pharmaceuticals during monitoring of a 5 km
length of the River Aire were of the order observed in the monthly
monitoring. The data indicate no appreciable reduction in phar-
maceutical concentrations along the reach (Fig. 3). The apparent
downstream increase in concentrations in some cases should be
treated with caution and is likely to be caused by higher efﬂuent
concentrations at the upstream sites leading to signal suppression
during LC-MS analysis. There was considerable variation in the
pharmaceutical concentrations measured at the same sites on
different dates although the lack of dissipation was consistent. The
lack of any consistent patterns across space and time as well as the
absence of a signiﬁcant relationship with ﬂow conditions across
diurnal sampling events (see supplementarymaterial S4) make this
difﬁcult to explain and it is likely that a range of factors contributed
to this variation which are discussed in Section 4.4.4. Discussion
The dataset presented here contributes to the knowledge base of
pharmaceutical occurrence in sewage efﬂuents and rivers and de-
tails how frequently they are present, the general concentrations at
which a range of compounds occur, changes over time, and dissi-
pation in rivers downstream of efﬂuent sources.4.1. Frequency of detection
The routine detection of the ﬁve study pharmaceuticals dem-
onstrates their widespread presence in river systems and pseudo-
persistence due to the continuous release of sewage efﬂuent.
Pharmaceuticals should therefore be considered as ubiquitous
pollutants in any freshwater ecosystem receiving sewage efﬂuent.
This ﬁnding is supported by similarly high detection frequencies
where pharmaceuticals have been monitored in other studies
(Hughes et al., 2013). Other studies have also reported high
detection frequencies for the compounds monitored in the current
Fig. 2. Mean (of two sampling occasions) pharmaceutical concentrations measured in the receiving waters of Garforth (a) and Oulton (b) wastewater treatments plants, UK, during
diurnal sampling events.
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2009), 3e100% for erythromycin (Kolpin et al., 2004; Kasprzyk-
Hordern et al., 2009), 1e100% for ibuprofen (Bound and
Voulvoulis, 2006; Focazio et al., 2008), 14e88% for mefenamic
acid (Kasprzyk-Hordern et al., 2009; Lopez-Roldan et al., 2010) and
37e100% for propranolol (Ashton et al., 2004). Whilst diclofenac
was detected at a similar frequency in sewage efﬂuent and river
water, erythromycin and ibuprofen were measured less frequently
in efﬂuent than receiving waters at our sites, potentially due to
matrix effects or release from unmonitored efﬂuent sources up-
stream (see Fig. 1) These include some of the largest WWTPs in
Yorkshire, such as Esholt (River Aire) and Deighton (River Calder)
which serve population equivalents of 760,000 and 680,000
respectively (Yorkshire Water, pers. comm.). Conversely, mefe-
namic acid and propranolol were detected less in receiving watersthan efﬂuent, potentially indicating more rapid dissipation in the
environment than the other study compounds.
4.2. Pharmaceutical concentrations in efﬂuent and receiving waters
More comprehensive monitoring than that undertaken in pre-
vious studies in the UK has identiﬁed concentrations of the study
compounds in treated efﬂuent and receiving waters of the same
order of magnitude as those previously reported (Petrie et al.,
2015). This provides greater certainty that the substances moni-
tored are present in sewage efﬂuent and receiving waters in the
range of single nanograms to micrograms per litre. Mean receiving
water concentrations were also very similar to global means re-
ported by Hughes et al. (2013) although peak concentrations are
lower than global maxima, due predominantly to the higher
Fig. 3. Concentration proﬁles for pharmaceuticals over a 5 km length of the River Aire, UK, downstream of Knostrop wastewater treatment plant (WWTP). Values are means of
seven replicates and error bars represent ±1 standard deviation. a ¼ diclofenac, b ¼ erythromycin, c ¼ ibuprofen, d ¼ mefenamic acid, e ¼ propranolol.
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efﬂuent concentrations were greater than those in receiving wa-
ters, presumably due to some dilution and removal by biotic and
abiotic processes. Nevertheless, peak concentrations for three of
the ﬁve study compounds were actually higher in the receiving
water than they were in efﬂuent. This could be due to signal sup-
pression in efﬂuent samples or pharmaceuticals being discharged
from upstream WWTPs and unknown sources such as septic tanks
and foul watermisconnections to surfacewater drains. Overall peak
and mean concentrations were of the same order of magnitude in
efﬂuent and receiving waters. This indicates that signiﬁcant dilu-
tion does not occur in river systems which receive large volumes of
efﬂuent, such as the Aire and Calder (Jürgens et al., 2002), where
extensive lengths of river carry concentrations of pharmaceuticals
and do not have the capacity to dilute downstream inputs.
Although the CSO dataset is small (n ¼ 14), frequent detection
indicates that raw sewage from sewer overﬂows is a signiﬁcant
source of pharmaceuticals to rivers. Moreover, given that concen-
trations in this raw efﬂuent, which logically will be the same as
WWTP inﬂuent, were of the same order as in WWTP efﬂuent it can
be hypothesised that the study compounds are not removed to anysigniﬁcant extent by WWTPs used in this study. Existing research
shows that pharmaceutical elimination rates in WWTPs can vary
greatly depending on a range of factors including concentrations in
raw sewage inputs and conditions in particular WWTPs (e.g.
Heberer, 2002; Carballa et al., 2004; Jones et al., 2007; Vieno and
Sillanp€a€a, 2014).
4.3. Temporal variations in pharmaceutical pollution
Very little work has been undertaken on the temporal variation
of pharmaceutical concentrations in rivers (Papageorgiou et al.,
2016) although Kanda et al. (2003) found ibuprofen concentra-
tions to peak in the middle of the day. This contrasts with the
current work where no obvious pattern was found. Moreover, no
consistent temporal pattern was found during the monthly sam-
pling of WWTP efﬂuents and receiving waters (supplementary
material S5). Winter peaks may occur due to increased pharma-
ceutical consumption, higher treatment efﬁciencies in WWTPs,
and reduced degradation in surface waters (MacLeod and Wong,
2010; Sui et al., 2011; Valcarcel et al., 2013; Lindholm-Lehto
et al., 2016). Conversely, some compounds have occurred in
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greater usage at this time of year (Lindholm-Lehto et al., 2016;
Papageorgiou et al., 2016).
4.4. Downstream proﬁles of pharmaceutical pollution
The consistent presence of the study compounds along a 5 km
reach of river suggests that in-stream dissipation along reaches of
several kilometres is negligible for the study compounds and that
exposure of freshwater ecosystems to pharmaceutical pollution
will occur well beyond the locality of WWTP discharges. The in-
stream fate of pharmaceuticals is poorly understood, with a
limited number of laboratory studies having been undertaken and
even fewer in the ﬁeld (Radke et al., 2010). In agreement with our
results, Radke et al. (2010) measured just 5e15% dissipation of
pharmaceuticals along a 14 km length of German river. In contrast,
however, Gross et al. (2004) demonstrated signiﬁcant removal (up
to 97%) of ibuprofen along a 11 km stretch of a shallow Californian
river due to reduced ﬂow, biodegradation and microbial trans-
formation (Lin et al., 2006) and greater light penetration in the
shallow river (Moss, 1988). Similarly, Fono et al. (2006) measured
high in-stream removal of ibuprofen along a >100 km reach of a
Texan river. The results presented here and elsewhere highlight the
need for caution when making assumptions about in-stream
pharmaceutical removal with rates likely to depend on site spe-
ciﬁc factors, individual compound properties, interaction with
sediments, latitude, season, weather, ﬂow, turbidity, hyporheic
exchange, microbial communities and dissolved organic carbon
concentrations (Kunkel and Radke, 2011). Nevertheless, the com-
pounds studied here had a range of physicochemical properties but
showed no appreciable difference in downstream fate. This is not
necessarily surprising given that, despite the fact that degradation
half-lives may vary between days and weeks (Kunkel and Radke,
2012), even the shortest of these will allow signiﬁcant transport
in a river. Moreover, suitable conditions (e.g. high suspended solids
concentration, contact with bed sediments) for sorption may not
exist even for hydrophobic compounds.
5. Conclusions
Despite much research on pharmaceuticals in the environment
during the last two decades there remain signiﬁcant knowledge
gaps, including a lack of repeat sampling, quantiﬁcation of spatial
and temporal patterns of pollution (e.g. in-stream dissipation,
seasonal and diurnal variation), and little monitoring of some po-
tential sources (e.g. CSOs). The current study found that the ﬁve
pharmaceuticals monitored are ubiquitous in rivers (present in
51e94% of samples) throughout urban and even semi-rural rivers.
Our results support the ﬁndings of other papers that pharmaceu-
ticals are routinely present in UK rivers at single ng to mg L1
concentrations. Mean concentrations were typically in the range of
tens to hundreds of ng L1. Although there is little legislation
regulating the presence of pharmaceuticals in rivers, the mean
measured concentration for diclofenac exceeded the proposed EQS
limit of 100 ng L1 by a factor of two. The scale of the pharma-
ceutical pollution problem is highlighted by the fact that only 6% of
samples monitored for pesticides in the UK exceed the same
threshold (Environment Agency, 2009). Pharmaceuticals must,
therefore, be seen as important environmental pollutants which
should be added to and regulated under existing policies (e.g.
European Commission, 2011). Concentrations varied over time
although no consistent patterns were found. Future monitoring
strategies should move towards robust sampling programmes
similar to those employed when monitoring more traditional pol-
lutants (Ort et al., 2010a). CSOs may be as relevant as WWTPs assources of drugs in rivers when they are discharging and must be
studied more and potentially managed better to limit the release of
untreated sewage to rivers. Of great importance is the observation
that pharmaceutical concentrations did not decline over a river
length of 5 km even though there were no known sources of
pharmaceuticals below the WWTP. Future research efforts must be
made to understand why this phenomenon has been observed in
this study and others. This understanding then needs to be incor-
porated into environmental risk assessment approaches.
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